Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)
This is a Phase 1b, randomized, placebo/vehicle-controlled, double-blinded, multi-center
trial. It is designed to assess the safety and efficacy of S. hominis A9 (ShA9) topical
application as a treatment for atopic dermatitis (AD). The trial will enroll adults and
ad...
Age: 12 years - 66+
Gender: All
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Monotherapy Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
This is a multinational, multicenter, randomized, double-blind, placebo-controlled,
parallel, Phase 3 study for treatment of participants aged 12 years and older diagnosed
with moderate-to-severe atopic dermatitis (AD).
The main objective of this study is to evalua...
Age: 12 years - 66+
Gender: All
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
The purpose of this study is to learn about the safety and effects of 2 study medicines
(PF-07275315 and PF-07264660) for the treatment of atopic dermatitis (AD). AD is a long-
lasting itchy red rash, caused by a skin reaction.
This study is seeking participants wh...
Age: 18 years - 66+
Gender: All
A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
The primary objective of this study is to describe the long-term safety and tolerability
of rocatinlimab in participants with moderate-to-severe AD.
Age: 12 - 100 years
Gender: All